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Abstract: The blood–brain barrier (BBB) hinders drug delivery to the brain. Despite various1
efforts to develop preprogramed actuation schemes for magnetic drug delivery, the unmodeled2
aggregation phenomenon limits drug delivery performance. This paper proposes a novel scheme3
with an aggregation model for a feed-forward magnetic actuation design. A simulation platform4
for aggregated particle delivery is developed and an actuation scheme is proposed to deliver5
aggregated magnetic nanoparticles (MNPs) using a discontinuous asymmetrical magnetic actuation.6
The experimental results with a Y-shaped channel indicated the success of the proposed scheme in7
steering and disaggregation. The delivery performance of the developed scheme was examined8
using a realistic, three-dimensional (3D) vessel simulation. Furthermore, the proposed scheme9
enhanced the transport and uptake of MNPs across the BBB in mice. The scheme presented here10
facilitates passage of particles across the BBB to the brain using an electromagnetic actuation scheme.11
12
Keywords: Asymmetrical discontinuous field function, blood–brain barrier (BBB), magnetic drug13
delivery, magnetic nanoparticles, aggregation.14
1. Introduction15
In recent years, many nanorobotic systems have emerged for studies in biology [1–5], and16
developments in magnetic nanoparticles (MNPs) for biomedical applications have considerably17
exceeded expectations, as the versatile natural properties of MNPs facilitate biological applications18
such as drug delivery. Functionalized MNPs showed encouraging results in crossing the blood–brain19
barrier (BBB) [6,7]. Magnetic drug delivery can be used to increase drug uptake. In magnetic drug20
delivery (MDD), the drug is added to MNPs, which are injected into a blood vessel and circulate21
throughout the vasculature. An external magnetic field is next applied to achieve the optimal22
concentration of drug-loaded particles in the desired location [8,9].23
MNPs have myriad applications as therapeutic and diagnostic agents. Recent studies of MNPs24
for MDD applications revealed their magnetic properties, biocompatibility, and toxicity [10]. MNPs25
have unique optical properties suitable for in vivo tracking and are capable of delivering drugs to26
brain cells [11]. Drug-conjugated MNPs are used for drug delivery [12,13] by applying an external27
magnetic field to a location of interest in the body.28
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Although drug delivery using a magnetic field has been around for decades [14], recent29
developments made MNPs feasible for MDD. Studies on MDD focused on simulation and analysis of30
the captured and retained particles using a constant external magnetic field. Numerical simulations31
of blood flow and MNP distribution in a realistic brain vessel demonstrated that MDD significantly32
increases particle capture [15]. Particle size, type and coating, which influence capture efficiency,33
were studied in a computer simulation; particle retention decreased with increasing particle size [16].34
However, particle sticking and aggregation were neglected in these simulations.35
The concentration of MNPs under a constant magnetic field using a Y-shaped bifurcation has36
been reported [17], and the aggregation of MNPs under a constant magnetic field has been examined37
experimentally [18]. MNPs reportedly stick to vessel walls due to the low flow velocity [19]. Steering38
of aggregated microparticles under a constant magnetic field in a Y-shaped channel resulted in the39
accumulation of aggregates at the bifurcation [20]. A constant magnetic field is used to facilitate40
passage across the BBB, which is mediated by endocytosis [21]. Real-time in vivo monitoring of drug41
delivery using a constant magnetic field has been evaluated [22]. Moreover, after crossing the BBB42
under the guidance of a uniform magnetic field, MNPs formed rod-shaped aggregates [23]. Although43
in [18] sticking was reduced by changing the shape of the magnet, this is not a general solution44
to sticking; indeed, despite successful passage across the BBB, sticking and aggregation were not45
considered in [21].46
We resolved particle sticking by simulating intentional changes in the magnetic field direction47
[24]. The use of dynamic magnetic actuation (change in field direction) to reduce aggregation was48
investigated in [25]. The findings in [26] showed that dynamic actuation with a pulse-shaped49
magnetic field using permanent magnets improves passage through the BBB. To evaluate drug uptake50
in the brain, time-varying dynamic magnetic actuation was evaluated in the brains of mice. In the51
absence of a magnetic field, no nanoparticles (NPs) were found in the brain [27]. Using magnetic52
field function, however, the rate of BBB passage and drug uptake increased significantly [27]. Despite53
the acceptable performance in vivo, aggregation in a magnetic field was not modeled. To improve54
dynamic actuation for BBB passage, particle aggregation should be modeled.55
Cluster structure and aggregation were previously evaluated numerically in a two-dimensional56
(2D) platform [28]. Vartholomeos and Mavroidis developed a simulation platform to aggregate MNPs57
and increase the magnetic force in a simulation [29]. A computational platform was designed to assess58
the guidance of aggregated particles under a constant magnetic field [30]. A simulation platform was59
also developed to deliver aggregated particles under a dynamic magnetic field in a Y-shaped channel60
[31]. However, a discontinuous magnetic actuation scheme that minimizes aggregation and increases61
the rate of BBB passage has not been reported to date.62
In this scheme, the NPs are injected into a vein and circulate through the vasculature. We63
propose a novel discontinuous asymmetrical dynamic actuation scheme to change the magnetic field64
and deliver MNPs. This method is aimed at facilitating BBB passage by minimizing aggregation65
through insertion of a deactivation time (Tdis) between each cycle, as shown in Fig. 1. A66
simulation platform is utilized to assess delivery of aggregated particles under the dynamic actuation67
scheme. A discontinuous asymmetrical field function (DAFF (t)), which generates a discontinuous68
unequal alternating magnetic gradient, enables changes in field direction to guide MNPs. The69
functionality and performance of this approach in terms of particle sticking were evaluated in a70
realistic three-dimensional (3D) simulation of a vessel. The proposed design improved BBB passage71
by MNPs and decreased the size of aggregates after BBB passage.72
This paper is organized as follows: in section 2, the computational model for particle guidance is73
developed, the concept and design of the DAFF are introduced, and the DAFF is studied for steering74
MNPs in a Y-shaped channel. In addition, the effects of DAFF on particle sticking are investigated in75
a realistic 3D vessel simulation. Finally, in vivo evaluation of passage through the BBB by MNPs is76
presented. Section 3 presents the setup of the experiments. We concluded that the proposed scheme77
increases the rate of BBB passage by MNPs.78
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Figure 1. Schematic of the discontinuous magnetic actuation system for drug delivery and
blood–brain barrier (BBB) passage using the proposed discontinuous asymmetrical field function
(DAFF).
2. Results and Discussion79
2.1. Governing Dynamic Forces in MDD80
To fully understand MNP aggregation, the forces governing MNP steering are modeled in this81
section. Many parameters presented in this section will be used throughout the manuscript; any82
changes in them will be stated. The forces depicted in Fig. 2 were considered and the Newtonian83
dynamic model is used:84
mi
dvi
dt
= FMF + Fdip + Fdrag + FCA + Fm (1)
where index i indicates particle i, mi is the particle mass, vi is the particle velocity, FMF is the magnetic85
force, Fdip is the dipole force, Fdrag is the hydrodynamic drag force, Fm is the gravitational force86
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Figure 2. T2 A particle i inside the vessel is considered; the effective forces are shown in the free-body
diagram and the geometry of the rod-shape aggregates is illustrated.
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(gravity and buoyancy), and FCA is the contact-adhesive force. To use Newtonian mechanics, particles87
are considered to be large enough to exclude the effect of Brownian motion [29,32].88
The magnetic force is the actuation force used for steering. MNPs exhibit almost hysteresis-free89
behavior. If the permeability in medium satisfies the relation µ1 = µ0 (µ0 is the permeability of the90
free space) and, considering the magnetic polarization (M) as a function of magnetic intensity (H),91
which has a finite limit of Msat, and the magnetic field is considered large enough to create the finite92
value Msat, and V is considered to be the volume of the rod-shaped aggregates, then the magnetic93
force can be modeled as:94
FMF = Vµ1Msat.∇H f (2)
The rod-shaped aggregates have a diameter of n2d and a height of n1d, with d being the diameter95
of a single MNP. n1 and n2 are the number of particles in the aggregate (the rod-shaped aggregates96
are shown in Fig. 2). The aggregate volume is represented as pi4 n1n
2
2d
3.97
Fdip is the dipole force, which plays a major role in keeping the particles together. The dipole98
force is modeled as:99
Fdip =
3µ1mimj
4pir4ij
(rij(mi.mj)
+mi(rij.mj) +mj(rij.mi)− 5rji(rji.mi)(rji.mj) (3)
where µ1 is the magnetic permeability of the medium, mi and mj are the magnetic moments of the ith100
and jth particles and rij is the distance between particles.101
During aggregation, the dipole force has two main effects: an initial negligible contribution to
magnetic intensity (H), and a major influence on particle-particle sticking. To model the magnetic
moment, a system of coupled equations must be solved [29,30]. The total magnetic intensity for the
particle of interest is given as:
H = Hext +
N
∑
j
Hdip (4)
where Hext is the external magnetic intensity, and sum is the accumulated effect of other particles.102
The drag (hydrodynamic) force on the particles based on Stokes law is:
Fdrag = −3piηd(vp − v f ) (5)
where vp and v f are the particle and fluid velocities, respectively, d is the particle diameter, and η is103
the fluid viscosity.104
The gravitational force is yielded by gravity and buoyancy forces as follows:105
Fm =
1
6
pid3(ρp − ρb)G (6)
where d is the particle diameter, ρp and ρb are the particle and blood densities, respectively.106
The contact-adhesive forces are generated by particle-particle or particle-surface collisions. The
Hertzian contact model can be expressed as:
Fc = kδ
3
2
If↔ Pdis < Ri + Rj (7)
where Pdis is the particle-particle distance, Ri is the ith particle radius, Rj is the jth particle radius, k is107
the spring constant, and δ is deformation.108
The adhesive force is also modeled as:
FAd = τpi
(3Fcd
8E∗
) 2
3 (8)
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Figure 3. Steering aggregated magnetic nanoparticles (MNPs) in a Y-shaped channel using magnetic
actuation.
where τ is the adhesive energy (a constant parameter), d is the equal diameter(d = 2 ∗ R1R2R1+R2 ),
Fc is the contact force, and E∗ is the equal elasticity module. The opposite nature of the contact force
(separation) and adhesion force (connection) creates the contact adhesive force, which is represented
as:
FCA = FAd + Fc (9)
The trajectories of the MNPs can be determined by incorporating the forces in Eq. 1.109
2.2. Simulation platform for steering aggregated MNPs in bifurcations110
A Y-shaped channel that resembles the bifurcation is used in the simulation. The Y-shaped111
channel consists of one inlet and two outlets of constant diameter. A steady creeping flow enters112
through the inlet and exits via the outlets. Aggregation is considered to occur near the inner boundary113
of the vessel. Initially, the particles attract each other due to dipole effects. The contact-adhesive force114
balances this effect and mediates MNP aggregation. The magnetic force acts as a body force and115
moves the particle toward the direction of application; the drag force resists this movement. These116
forces are incorporated into the governing dynamic (Eq. 1), and a system of ordinary differential117
equations (ODEs) is formed.118
In this simulation, 225 particles (800 nm diameter) were used and a system of 900 ODE equations119
is solved at each time step. The ODE system is numerically solved using the Runge Kutta method.120
The magnetic and drag forces govern the dynamics of the movement of particles inside the vessel. The121
magnitude of the magnetic forces varies with the number of aggregated particles in a rod. Therefore,122
particle velocity varies according to aggregate size. The number of particles in aggregates determines123
the velocity; therefore, aggregate size is used in the simulation to match the experimental data [31,33].124
Fig. 3 shows a simulation of MNP aggregation within a Y-shaped channel. The rod-shaped125
aggregates move based on the magnetic actuation at different velocities, and reach the bifurcation.126
Using this simulation platform, which considers the physical parameters in Table 1, guidance can be127
evaluated by computing the number of particles that reach the correct outlet. It was assumed that128
particles that remain inside the safe zone will be guided to the correct outlet [33]. The safe zone is the129
distance between the vessel boundary of the correct outlet and the mid-vessel line (Fig. 3). A high130
percentage of particles reaching the correct outlet reflects the delivery performance of the MNPs by131
the magnetic field.132
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Table 1. Simulation Parameters.
Parameter value
Particle density 6450 kg/m3
Particle diameter 800 nm
Blood density 1050 kg/m3
Blood viscosity 0.004 Pa.s
Air relative permeability 1 Dimensionless
Blood relative permeability 1 Dimensionless
Blood temperature 293.15 K
2.2.1. The Influential Parameters in Targeting Performance133
Three coefficients were introduced to investigate the effect of aggregation on guidance. The134
guidance performance in a Y-shaped bifurcation depends on the vessel elongation ratio (Rve) for the135
vessel geometry, normal exit time (Tc) as an environmental condition, and the force factor (R f ) [24].136
The normal exit time represented by Tc shows the influence of vessel elongation and flow137
velocity. This factor represents the minimum time needed for the aggregated particles to reach the138
bifurcation point. In the vascular network, the blood-flow velocity varies between a few millimeters139
per second in capillaries to a few centimeters per second in arteries [20]. The normal exit time is140
shown in Eq. (10). The designed actuation should be robust to these changes and be able to safely141
guide the particle to the desired outlet. To study this effect, the vessel nominal length is considered142
to be 10 mm and the normal exit time varies based on the information in Table 2.143
Tc =
( Lv
Vb
) (10)
where Lv is the vessel length and Vb is the flow velocity.144
The diameter and length of blood vessels vary; this is represented by the vessel elongation ratio145
Rve, which is considered to a dimensionless factor comprising the vessel length to diameter ratio. To146
study this parameter, the vessel nominal length is considered to be 10 mm and the Rve is changed147
based on the information in Table 2. The vessel elongation factor is:148
Rve =
( Lv
Dv
) (11)
where Lv is the vessel length and Dv is the vessel diameter.149
The magnetic actuation force is mainly affected by two parameters: the magnitude of the
magnetic field gradient and the particle size. To evaluate the effect of the actuation force, the force
factor is defined as:
R f =
(
Hgd3) (12)
where Hg is the magnetic gradient and d is the particle diameter. The particle diameter is considered150
to have a mean value of 800 nm and the force factor used in the simulations is presented in Table 2.151
The ability of a constant-direction magnetic field to steer MNPs is reportedly limited by particles
sticking to the vessel. This can be solved by alternating the dynamic magnetic actuation [24]. A field
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Table 2. Units for Magnetic Properties.
Symbol Quantity unit
Lv Vessel length 10 mm
Tc Normal exit time 5 s
Rve Vessel elongation 20, 10, 6.6, 0.5 Dimentionless
R f Force Factor 0.3, 0.6, 0.9, 1.2, 1.5, 1.8 pA.m
function (FF(t)), which is a unitless multiplier, is proposed to change the direction of the magnetic
field by activating the coils sequentially [24]. (FF(t)) for all values of t is defined as:
−1 ≤ FF(t) ≤ 1 (13)
Here, the minus sign indicates the right coil (direction of incorrect outlet) and the plus sign indicates152
the left coil (direction of the correct outlet) (Fig. 1). This function defines the magnetic field, and has153
two properties: the frequency (Hz) and duty ratio (dimensionless) of activation time. The ratio of the154
activation time for the coil in the direction of the correct outlet to the activation time for the coil in the155
direction of the incorrect outlet is considered to be 3 to 1. Different frequencies were considered for156
simulation of MNP guidance [24]. Using FF(t), the alternating gradient field is defined as:157
∇H f = FF(t)∇H (14)
Consequently, the actuation force is designed as:158
FMF = FF(t)VMsat.∇H (15)
The frequency of the FF(t) (Fig. 4 A) is considered to be 0.5 Hz, which is the best frequency159
suggested in [24]. However, the previous simulation did not consider the effects of the aggregation160
of MNPs within the magnetic field. A previously developed computational platform (Fig. 3) with161
aggregation modeling is used to study the guidance performance of aggregated MNPs. The number162
of particles reaching the correct outlet is calculated. The simulation results for aggregated particle163
guidance for all conditions in Table 2 are shown in Fig. 4.164
The simulation results reveal two patterns of aggregated particle guidance with the FF(t)165
(Fig. 4). By increasing the force factor (from R f = 0.3 to 1.84), the success rate decreases in all166
cases. This is because when a higher force is applied, more particles leave the safe zone, and so167
guidance performance is decreased by the increase in the force factor. Therefore, an obvious trend168
of deterioration is observable for higher force factors. Moreover, a decrease in the vessel elongation169
factor results in an increase in the rate of successful guidance (Fig. 4). As the vessel elongation factor170
increases, the time needed for the particles to leave the safe zone increases. In this simulation, as the171
particles are considered to be aggregated, the normal exit time is not very influential.172
As illustrated in Fig. 4, the delivery performance of FF (t) is sensitive to parameter changes.173
Moreover, the magnetic actuation (FF(t)) proposed in [24]) does not include the effects of aggregation174
and it generates large aggregates that hinder BBB crossing. Therefore, this paper uses a discontinuous175
asymmetrical field function to solve these issues.176
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Figure 4. Simulation results for aggregated particle guidance. A) The field function for magnetic
actuation, B) The delivery performance in a simulation of a Y-shaped vessel with dv=1 mm, Lv=10
mm, Tn=5 s and field function (FF) (t) with 6A and duty cycle of 0.5 Hz.
2.2.2. The DAFF Design177
The magnetic actuation scheme should be modified to reduce the adverse effects of aggregation.
Therefore, we propose a DAFF to solve the aggregation issue. The DAFF is a unit-less multiplier
with an asymmetric ratio of α and a magnitude of 1. The asymmetry ratio α is used to handle the
aggregation effect and keep particles inside the safe zone (illustrated in Fig. 3). The DAFF also
alternates the magnitude of the magnetic field sequentially. The DAFF(t) is illustrated in Fig. 1 and
for all values of t is defined as:
−α ≤ DAFF(t) ≤ 1 α ≤ 1 (16)
Here, the minus sign indicates the right coil (to the incorrect outlet) and the plus sign indicates178
the left coil (to the correct outlet), as illustrated in Fig. 1.179
In the absence of a magnetic force, the aggregated particles disaggregate due to the effects of180
Brownian and drag forces. Tdis is the time of discontinuity, in which both coils are inactive, considered181
in the DAFF. The DAFF is defined by the activation ratio, discontinuity time (Tdis), frequency, and182
asymmetry ratio (α). DAFF has an activation ratio of 2 to 1 (for the coils) and the Tdis is considered to183
be equal to Tminus (Fig. 1). The magnetic actuation force is introduced as:184
FMF = DAFF(t)VMsat.∇H (17)
The design objective here is to determine the magnitude of α (asymmetry ratio) and frequency185
so that retains all particles inside the safe zone (Fig. 3). With the designed frequency and asymmetry186
ratio, the particles will remain in the safe zone and can reach the correct outlet. Utilizing the187
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developed computational platform, the frequency and α are obtained to satisfy the design objective.188
The simulation flowchart for the discontinuous asymmetrical field function is shown in Fig. 5.189
The current applied to the coils is 1, 2, 3, 4, 5, and 6 A [27]. Therefore, the asymmetry ratio α is190
considered to be 0.16, 0.33, 0.5, 0.66, 0.83, and 1, respectively. For a predefined bifurcation geometry191
with a diameter of 1 mm and length of 10 mm. Initially, the asymmetry ratio α is considered to be192
0.16. In step 1, the actuation frequency is considered to be 1 Hz; then, the simulation platform is193
used to verify that all particles remain in the safe zone. If all particles remain in the safe zone, the194
frequency is decreased in 0.1 Hz increments. This cycle repeats unless the particles exit the safe zone.195
The minimum frequency that retains all aggregates inside the safe zone is obtained. In step 2, the196
asymmetry ratio α is increased; this process is repeated for different values of α (0.16, 0.33, 0.5, 0.66,197
0.83, 1). In step 3, the vessel diameter is changed (2 and 3 mm), and the above process is repeated to198
determine the adequate frequency for each vessel diameter. The flowchart in Fig. 5 shows the process199
of determining the adequate frequency according to the asymmetry ratio in the DAFF and the vessel200
diameter.201
Fig. 6 shows the relation between frequency and asymmetry ratio (α), based on the flowchart in202
Fig. 5. Using the frequency and asymmetry ratio in Fig. 6 for DAFF, 100% guidance is achieved in203
the simulation. In addition, Fig. 6 indicates that, for lower asymmetry ratios (α), a lower frequency204
can be applied, and the frequency increases with the rise in asymmetry ratio. A high frequency does205
not provide sufficient guidance and delivery performance [27,34]. Therefore, a low asymmetry ratio206
(α = 0.133 and 0.33) and low frequency are used in this study.207
2.3. In vitro study of guidance of MNPs in a Y-shaped channel208
The experimental setup of the magnetic actuation platform is shown in Fig. 7. Electromagnetic209
actuators are designed to generate an adequate magnetic force to steer MNPs within the region of210
interest.211
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Fig. 8 shows the video image data for steering performance in FF and DAFF experiments, with212
the aim of providing a qualitative understanding of the different guidance behaviors of the FF and213
DAFF.214
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Figure 7. A) The electromagnetic actuator comprises two coils (5,000 turns and diameter of wire dw
= 1.0 mm) with two cores to increase the magnetic field density (cobalt–iron alloy VACOFLUX 50,
VACUUMSCHMELZE, German); the cores are 19.5 cm in length and 6 cm in diameter. Two power
supplies (AMETEK SGA 600/17, 10 kW) are utilized to generate currents of up to 6 A (gradient field
strength, 2.8 T/m) in the experiments. B) Schematic of the system.
Aggregated particles move through the channel, as shown in the supplementary video. The215
aggregates are oriented along the direction of the main magnetic field and move with the flow. In216
the absence of a magnetic field, particles flow similarly through both outlets. As the magnetic field217
with FF (0.5 Hz, 6 A) is applied, the aggregates move toward the correct outlet. A sudden change in218
the magnetic field results in aggregates entering the incorrect outlet (Fig. 8A) (supplemental video).219
Some aggregates accumulate at the branch of the channel and the boundary of the vessel; these form220
stationary aggregates.221
Fig. 8B shows combined images obtained by averaging multiple video frames. These plots show222
aggregate accumulation during the steering experiments. The black parts of the images represent223
areas with the highest density of aggregates. Consistent with the simulation platform described224
in the previous section, these results represent the scenario in which the guidance performance of225
the aggregates fluctuates under FF and many particles enter the incorrect outlet. The formation of226
rod-shaped aggregates is also verified in this image. This phenomenon can be observed in Fig. 8B.227
Although a pulsed magnetic field reduced blood clotting compared with a constant magnetic field228
[20,30], stationary aggregates and aggregates entering the wrong outlet can lead to blood clotting.229
Therefore, the DAFF is proposed to prevent blood clotting caused by aggregates.230
As the magnetic field with DAFF (0.144 Hz, α = 0.16) is applied, the aggregates move smoothly231
toward the correct outlet (Fig. 8C and supplemental video). The size of the aggregates is reduced232
significantly and stationary aggregates do not appear. Fig. 8D shows combined images. Black parts233
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of the images represent areas with the highest density of MNPs. These results confirm that the DAFF234
improves guidance of the MNPs. The DAFF also reduced the size of aggregates.235
Three differences between Fig. 8D and B are evident. The size of aggregates is reduced by use236
of the DAFF for steering, aggregate fluctuations and entry to the incorrect outlet are minimized, and237
there are no stationary aggregates in the incorrect outlet or at the boundary. Statistical analysis of238
the images in Fig. 8B and D verifies these phenomena. Fig. 8E shows that accumulation of particles239
in the correct outlet is twofold greater than that with the DAFF, which indicates that the aggregates240
are larger. Moreover, particles are absent from the incorrect outlet with DAFF, but for FF, 8.5% of241
the incorrect outlet is covered with MNPs. These results can be also seen in Fig. 8B and D and the242
supplementary movie. By eliminating stationary aggregates and reducing aggregate size, the DAFF243
reduces the risk of blood clotting.244
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2.4. Realistic model simulation245
To study the effects of the DAFF, a realistic 3D model was simulated in COMSOL. A246
special procedure was used to extract data from a magnetic resonance image (MRI) and create a247
computer-aided design (CAD) model [35]. The model was imported into COMSOL Multiphysics248
to assess particle trajectory. The realistic model consists of one inlet and six outlets with different249
diameters.250
The average inlet velocity is selected based on a realistic blood velocity (10 mm/s) and the CFD251
module of COMSOL is used to obtain the velocity profiles in all channels. Other parameters are252
included in the simulation using the values in Table 1. The experimental studies in [36] suggested that253
30% of MNPs are single particles and the magnetic actuation cannot guide them. In the simulation,254
1,000 800-nm-diameter particles are realized uniformly in the inlet and their trajectories are recorded.255
To illustrate the aggregation effects, 30% of the particles are considered to be single particles, and 70%256
to be aggregates. Based on the aggregate geometry (Fig. 2), the equal diameter is considered to be:257
deq =
pi
2
n1n22d
3 (18)
where n1 and n2 are simulation parameters for the geometry of rod-shaped aggregates (Fig.258
2), and d is the particle diameter. The equal radius for the aggregates is considered to match the259
experimental results in [31]. Guidance for delivering MNPs under the designed actuation is studied260
statistically, and the number of particles reaching each outlet is calculated using the trajectory module261
of COMSOL.262
To assess differences in particle trajectories, the simulation time is initially considered to be Ts=7s263
for both FF(t) and DAFF(t); the trajectories are simulated in Fig. 9. Although FF resolves the sticking264
issue during movement of the MNPs, a sudden position change is observed and the particles reach the265
opposite side, which leads to MNP fluctuations within the vessel and limits guidance performance.266
By contrast, the DAFF yields smoother movements, which indicates stable steering performance.267
 
 
 
 
 
 
 
 
 
 
 
 
 
A) FF (t) 
Sudden change in the 
particles position and 
particles reach the other side 
of the vessel  
B) DAFF (t) 
Smooth change in the 
particles position and 
particles remain in the 
desired side   
Figure 9. Particle tracking simulation of Ts = 7s for A) a field function (FF(t)) and B) a discontinuous
asymmetrical field function (DAFF(t)).
Fig. 10A shows the simulated vessel geometry. The effects of magnetic functions are studied in268
this simulation. Fig. 10B shows that in the absence of a magnetic field, only 13.7% of the particles269
reach the targeted outlet, and particles are distributed based on the drag force effects (Fig. 10B shows270
the delivery performance). Fig. 10C shows the effects of a constant magnetic field, which exacerbates271
the sticking issue; 73.7% of the particles remain within the vessel and only 3% reach the outlet. By272
contrast, although the field function (6 A and 0.5 Hz) resolves the sticking issue and 3.9% of the273
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particles remain in the vessel (Fig. 10D), the number of particles in the targeted outlet increases only274
slightly to 11.4%. In comparison, for DAFF with α = 0.166 and a frequency of 0.144 Hz (Fig. 10E),275
the number of particles reaching the targeted outlet increased significantly (72.2% for DAFF) due to276
the smooth movement of the particles in the vessel. By alternating the field direction, outlet 6 is also277
considered for delivery; using the same DAFF in this direction, 76.8% of the particles are delivered.278
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Remain 269 
Remain 754 
73
15
38
16
104
0
275
17
38
16
540
0
648
Remain 114 
16
36
14
1080
743
16
36
16
108
0
Remain 178 
Remain 71 
Magnetic Field Direction 
Magnetic Field Direction 
Magnetic Field Direction 
Magnetic Field Direction 
 
8.12 out
4.21 out
1.33 out
24 out
1.25 out
6.26 out
9.4in
Length=156.4 Width=87.6 
All dimensions are in millimeter 
A) Geometry of the vessel B) No Magnetic Field C) Constant Magnetic Field 
E) Discontinues Asymmetrical Magnetic Field 
Function (DAFF (t))  
 
F) Discontinues Asymmetrical Magnetic Field 
Function (DAFF (t))) 
Field Direction 
Field Direction 
Field Direction 
Field Direction 
D) Magnetic Field Function (FF (t)) 
272
93
44
92
362
0
Remain 137 
Remain 737 
73
30
14
39
110
0
74
114
14
486
273
0
74
722
12
40
111
0
768
28
15
37
111
0
Remain 39 
Remain 41 
Remain 41 
Figure 10. The simulation of the MNP distribution in a realistic vessel under the different designed
actuation functions. The number close to each outlet is the number of particles reaching that outlet:
A) the realistic vessel geometry; B) the distribution of particles under a drag force in the absence of a
magnetic field; C) a constant magnetic field; D) the FF; and E) the discontinuous asymmetrical FF.
2.5. Passage of the BBB279
[37] confirmed the passage of NPs through blood vessels in vivo under a magnetic force. They280
show the BBB being crossed under a magnetic field inside vessels using atomic force microscopy281
(AFM). In this section, we show the particles after crossing the BBB under a magnetic field, which is282
in agreement with the results in [27,37].283
Superparamagnetic iron oxide (SPIO) NPs satisfy the conventional cytotoxicity assessment, but284
once they are exposed to a static magnetic field their aggregation adversely affects their toxicity [38].285
However, the coating reduces both the aggregation and toxicity of the NPs [39]. One of the main286
objectives of our paper was to reduce aggregation by using discontinuous asymmetrical magnetic287
actuation. Therefore, the combined effects of coating and DAFF have a positive effect on reducing288
toxicity.289
Pulse-shaped magnetic fields enhance passage through the BBB [26]. However, the functionality290
is limited by unmodeled aggregation. The in vitro experiments in this paper showed the destructive291
effect of aggregation. Therefore, the DAFF is designed to disaggregate the MNPs and improve the292
delivery of NPs to the brain. To examine the effects of the proposed actuation scheme in vivo, several293
experiments were conducted using the experimental setup in Fig. 7 and test subjects were positioned294
inside the ROI (Fig. 1).295
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Fluorescent MNPs (FMNPs) were injected into mice via the tail vein and then exposed to296
magnetic field conditions for 10 mins. FMNP uptake in the brain was verified using confocal297
microscopy. Fig. 11 shows confocal microscopy images of mouse brains under DAFF (Fig. 11(A)), FF298
(Fig. 11(B)), and no magnetic field (Fig. 11(C)). We first analyzed the brains of mice in the absence299
of a magnetic field; no accumulation of FMNPs in the brain was observed (Fig. 11C). FMNP uptake300
and transport were significantly higher for all magnetic actuations (Fig. 11D 1-2) compared with301
the control group (Fig. 11D 3). Interestingly, compared with the best condition for FF, which was302
introduced in [27], the rate of particle transport across the BBB was increased significantly (1.5-fold)303
under condition 1 (DAFF, α = 0.16), which showed that a discontinuous asymmetrical field function304
improved FMNP uptake and transport to the mouse brain compared with FF (Fig. 11D).305
Fig. 12 shows the average size of MNPs in the brain after crossing the BBB. Fig. 12A and B306
illustrates particle detection and categorization after BBB crossing under DAFF and FF. Fig. 12B shows307
the average size of aggregates. Aggregates in condition 2 (FF) had a larger average size than those308
in condition 1 (DAFF). Therefore, DAFF can be used to enhance the transport of MNPs across the309
BBB, while resulting in markedly smaller aggregates. More importantly, our results demonstrate the310
importance of exploring the effects of variation in the magnetic field in the context of in vivo drug311
delivery applications.312
 
 
 
  
Figure 11. Confocal microscopy images of brain tissue samples: A) DAFF(t), 6 A, α = 0.16, 0.144
Hz, B) FF(t), 6 A, 0.5 Hz [27], C) control, and D) MNP accumulation. Data are the mean ± SEM of
triplicate experiments (n = 3), 1) DAFF(t), 6 A, α = 0.16, 0.144 Hz, 2) FF(t), 6 A, 0.5 Hz, and 3) control.
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Figure 12. Aggregation of fluorescent MNPs (FMNPs) after crossing the BBB with different magnetic
FFs. Aggregates under A) discontinuous asymmetrical field function (DAFF) and B) FF. C) MNP
accumulation under 1) DAFF(t), 6 A, α = 0.16, 0.144 Hz and 2) FF(t), 6 A, 0.5 Hz.
3. Experimental Section313
3.1. System setup314
The region of interest is 60 mm in diameter at the center of the actuation system. The315
electromagnetic actuator comprises two coils (5,000 turns, wire diameter dw = 1.0 mm) with two cores316
to increase the magnetic field intensity (cobalt–iron alloy VACOFLUX 50; VACUUMSCHMELZE,317
Hanau, Germany); the cores are 19.5 cm in length and 6 cm in diameter. Two power supplies (SGA318
600/17, 10 kW; AMETEK, Berwyn, PA, USA) are used to generate currents of up to 17 A (maximum319
gradient field strength, 7.9 T/m). In the experiments, a maximum current of 6 A (2.8 T/m) is used320
[34]. An NI PXIe 8135 is used to control the coils and a digital microscope is used to monitor the321
MNPs.322
3.2. In vitro study323
To assess the DAFF experimentally, magnetic silica particles (SiMAG-Silanol, 750 nm diameter;324
Chemicell GmbH, Berlin, Germany) were guided within a Y-shaped channel using the proposed325
dynamic magnetic actuation. A Y-shaped channel with a length of 5 mm and diameter of 1 mm,326
with equal stream flows in both outlets, is used to study guidance performance.327
3.3. In vivo study328
Fluorescent carboxyl magnetic particles Nile Red (FMNPs), 1% w/v (CATALOG NO:329
FCM-02556-2), were purchased from Spherotech (Libertyville, IL, USA). The NPs were 0.20–0.39330
µm in diameter and were used in a previous study of drug delivery to the brain [27]. Nile Red331
is polymerized inside the core of the beads during the manufacturing process. In brief, the bead332
is polymerized in the first step with the Nile Red, magnetite, and styrene. The fluorescent tag is333
attached with NPs (FMNPs) and the excitation spectra of these FMNPs ranged from 400 to 500 nm,334
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and showed highly efficient fluorescence in the FITC channel at 488 nm when observed under a335
confocal laser scanning microscope (FLUOVIEW FV1000; Olympus, Tokyo, Japan), with an argon336
ion laser. The power of the laser was 20%. During the confocal microscopy experiment, we used337
DAPI dye to label the nuclei of the brain cells. To trace the FMNPs inside the mouse brain, the dye338
was attached to the magnetic particles before injecting them into the mouse, so there was no need339
for additional staining with the same dye to trace these particles inside the brain. The FMNPs were340
traced inside the brain with the help of the fluorescent molecules already attached to the magnetic341
particles; these were visible in the FITC channel at 488 nm (Figure. 11)342
Male wild-type C57BL/6N mice (25–30 g, 8 weeks old) were purchased from Samtako Bio343
(Gyeonggi-do, South Korea). The mice were acclimatized for 1 week in the university animal house344
under a 12-h/12-h light/dark cycle at 23 ◦C and 60% humidity, and provided with food and water ad345
libitum. The mice were divided randomly into the following groups: A) DAFF(t), 6 A, α = 0.16, 0.144346
Hz, B) FF(t), 6 A, 0.5 Hz, and C) Control. The mice in groups A and B received 0.4 mL of FMNPs347
via intravenous (i.v.) injection and were then exposed to the magnetic field for 10 minutes. The348
control animals were given 0.4 mL of 0.9% saline solution i.v. The mice were euthanized following349
the treatments. All efforts were made to minimize the number of mice used and their suffering. The350
experimental procedures were approved by the Animal Ethics Committee of the Division of Applied351
Life Sciences, Department of Biology, Gyeongsang National University, South Korea.352
Brain tissues from all of the groups were collected after the treatments. Transcardial perfusion353
was performed with 1× phosphate-buffered saline (PBS) followed by 4% ice cold paraformaldehyde.354
The brain tissues were post-fixed overnight in 4% paraformaldehyde and then transferred to 20%355
sucrose until they sank to the bottom of the tube. The brains were frozen in OCT (Tissue-Tek O.C.T.356
compound; Sakura Finetek USA, Torrance, CA, USA) and then cut into 14-µm sections in the coronal357
plane with a CM 3050S cryostat (Leica, Wetzlar, Germany). The sections were thaw-mounted on358
Probe-On positively charged slides (Thermo Fisher Scientific, Waltham, MA, USA) and stored at −70359
◦C.360
The brain tissue slides were dried overnight and then washed twice with 0.01M PBS for 15 min361
each. The tissue sections were stained with DAPI for 10 min, rinsed with PBS, and glass coverslips362
were mounted on the slides with a fluorescent mounting medium. Images were captured using a363
confocal microscope (FLUOVIEW FV 1000; Olympus).364
4. Conclusion365
A novel magnetic field function design that can minimize aggregation effects was proposed.366
The proposed discontinuous asymmetrical field function was simulated by a computational platform367
to study targeting performance in a Y-shaped vessel. A discontinuous asymmetrical field function368
was designed to achieve guidance performance of 100%. Then, we showed experimentally that the369
proposed discontinuous asymmetrical field function can increase delivery performance via steering370
at the bifurcation in vitro. The size of aggregates is also reduced in comparison with FF. Furthermore,371
stationary aggregates are absent in the presence of a DAFF. In vivo experiments also revealed the372
effectiveness of DAFF in terms of BBB passage. Image analysis reveals that, compared with FF, DAFF373
results in the generation of smaller aggregates after passage of the BBB. DAFF (6 A, α = 0.16, 0.144374
Hz) performed the best at BBB passage and drug uptake. The new actuation scheme, which was375
examined experimentally for MNP guidance and passage of the BBB, shows promising results. The376
mechanism of BBB passage, and determination of the optimum actuation function to enhance BBB377
passage, should be the subjects of future work.378
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